DEFA14A: Alkermes to Acquire Avadel for $2.1B, Boosting Sleep Medicine Portfolio

Alkermes plc will acquire Avadel Pharmaceuticals plc for up to $20.00 per share, including a contingent value right, to expand its presence in the sleep medicine market.

Summary

• Alkermes plc will acquire Avadel Pharmaceuticals plc for a total consideration of up to $20.00 per share, valuing Avadel at approximately $2.1 billion on a fully diluted basis.
• The acquisition price includes $18.50 per share in cash at closing and a non-transferable contingent value right (CVR) for a potential additional cash payment of $1.50 per share.
• The CVR payment is contingent upon two milestones: FDA approval of LUMRYZ for idiopathic hypersomnia in adults and the dismissal of specific patent infringement claims with Jazz Pharmaceuticals, Inc. by December 31, 2028.
• The transaction represents a premium of approximately 38% to Avadel's three-month weighted average trading price and 12% to its closing price on October 21, 2025, assuming the CVR is paid.
• Avadel's board of directors has unanimously approved and recommended the acquisition to its shareholders.
• The acquisition is expected to close in the first quarter of 2026, subject to shareholder and regulatory approvals, including U.S. antitrust clearances.
• Alkermes plans to finance the acquisition using cash on hand and $1.2 billion in new debt financing from JPMorgan Chase Bank, N.A.
• LUMRYZ, Avadel's FDA-approved once-at-bedtime oxybate for narcolepsy, had approximately 3,100 patients on therapy as of June 30, 2025, with net revenues expected to be $265 $275 million in 2025.

Sentiment

Score: 8

Explanation: The filing announces a strategic acquisition at a significant premium, with clear financial and strategic benefits for both companies, particularly for Avadel shareholders and Alkermes' market position in sleep medicine. The CVR adds potential upside, though its contingency introduces some uncertainty. The overall tone and projected outcomes are highly positive.

Positives

• The acquisition accelerates Alkermes' entry into the high-growth sleep medicine market.
• LUMRYZ, Avadel's key product, has shown strong market uptake since its 2023 launch, with new patient starts outpacing competitors by more than 2:1 since July 2023.
• The transaction is expected to be immediately accretive to Alkermes' earnings and enhance its revenue growth profile and profitability upon closing.
• Avadel's established commercial infrastructure and rare disease experience provide a strong foundation for Alkermes' potential launch of alixorexton, an orexin 2 receptor agonist candidate for narcolepsy and idiopathic hypersomnia.
• The combined financial strength will support a broad development strategy for Alkermes' orexin 2 receptor agonists (ALKS 4510 and ALKS 7290 in Phase 1 studies).
• Combined resources will support potential label expansion opportunities for LUMRYZ (currently in Phase 3 for idiopathic hypersomnia) and advancement of valiloxybate.
• The CVR offers Avadel shareholders a potential additional cash payment of $1.50 per share, contingent on future milestones, providing upside potential.
• The acquisition offers a significant premium to Avadel shareholders, including 38% to the three-month weighted average trading price and 12% to the closing price on October 21, 2025 (assuming CVR payment).

Negatives

• The CVR is non-transferable and its payment is contingent on specific milestones (FDA approval and legal dismissal) by December 31, 2028, with no certainty of achievement, meaning the CVR could be worth $0.
• Integration of operations is expected to drive cost synergies and operational efficiencies, which may involve some operational and administrative reorganization of the Company Group, potentially affecting employees.
• Certain central corporate and support functions of Avadel, particularly those related to its status as a listed company, may be reduced in scope or no longer required on a standalone basis.

Risks

• No assurance that the CVR Milestone (FDA approval of LUMRYZ for idiopathic hypersomnia and dismissal of specific Jazz Pharmaceuticals claims) will be achieved prior to the December 31, 2028 expiration, or that any payment will be made.
• Potential delays in consummating the acquisition due to regulatory approvals, shareholder approvals, or other conditions.
• The expected benefits and synergies of the acquisition may not be achieved, and the businesses of Alkermes and Avadel may not be effectively integrated.
• Significant changes in transaction costs and/or unknown or inestimable liabilities and potential litigation associated with the planned acquisition.
• General economic, political, market, and business conditions, or future exchange and interest rates, changes in tax laws, regulations, rates, and policies, may negatively impact the combined organization.
• The announcement or pendency of the planned acquisition could disrupt business and make it more difficult to maintain business and operational relationships, including attracting and retaining highly qualified personnel.
• Clinical development activities for product candidates may not be initiated or completed on expected timelines or at all, or results may not be positive or predictive of future outcomes.
• FDA or other regulatory authorities may not agree with regulatory approval strategies or may make adverse decisions regarding products.
• Products may prove difficult to manufacture, be precluded from commercialization by third-party proprietary rights, or have unintended side effects, adverse reactions, or incidents of misuse.
• Reduction in payment rate or reimbursement for products or an increase in related financial obligations to government payers.

Future Outlook

Alkermes anticipates that the acquisition will accelerate its commercial entry into the sleep medicine market and enhance its ability to develop its late-stage pipeline for central disorders of hypersomnolence. The transaction is expected to be immediately accretive and enhance profitability. Future plans include advancing alixorexton into a Phase 3 program for narcolepsy, supporting a broad development strategy for other orexin 2 receptor agonists (ALKS 4510 and ALKS 7290), and pursuing label expansion opportunities for LUMRYZ (currently in Phase 3 for idiopathic hypersomnia) and valiloxybate. Cost synergies and operational efficiencies are also expected from integrating Avadel's operations.

Management Comments

• Richard Pops, CEO of Alkermes: "This transaction represents a pivotal step in Alkermes' strategic evolution. With the acquisition of Avadel, we are able to accelerate our commercial entry into the sleep medicine market at a critical inflection point as we prepare to advance alixorexton into a phase 3 program in narcolepsy. Avadel's innovative portfolio, commercial capabilities and dedicated employees provide a strong foundation for growth in this therapeutic area. Enabled by our strong balance sheet, this all-cash transaction enhances our revenue growth profile and is expected to be immediately accretive, reinforcing our commitment to delivering long-term value for shareholders."
• Greg Divis, CEO of Avadel: "This transaction represents a compelling outcome for our shareholders and a powerful validation of our strategy, execution, commercial capabilities and the differentiated value of LUMRYZ. We've built a company deeply committed to transforming the lives of people living with narcolepsy, and I'm incredibly proud of what our team has accomplished. Alkermes shares our passion for innovation and patient impact and, together, we will continue this important work on behalf of people living with central disorders of hypersomnolence."

Industry Context

This acquisition positions Alkermes as a significant player in the sleep medicine market, a therapeutic area with substantial unmet needs, particularly for narcolepsy and idiopathic hypersomnia. The market for oxybate-eligible narcolepsy patients in the U.S. is estimated at over 50,000. By acquiring LUMRYZ, a differentiated once-at-bedtime oxybate, Alkermes gains a strong commercial product and platform to leverage its own pipeline of orexin 2 receptor agonists, such as alixorexton, ALKS 4510, and ALKS 7290. This move reflects a broader industry trend of consolidation and strategic acquisitions to expand therapeutic portfolios and achieve commercial scale in specialized markets.

Comparison to Industry Standards

• LUMRYZ's new patient starts outpacing the twice-nightly mixed-salts competitor by more than 2:1 since July 2023 indicates strong market acceptance and differentiation within the oxybate market for narcolepsy. This suggests a competitive advantage over existing treatments like Jazz Pharmaceuticals' Xyrem/Xywav, which require twice-nightly dosing.
• The acquisition premium of 38% to the three-month weighted average trading price is substantial, reflecting the strategic value of LUMRYZ and Avadel's commercial capabilities in the rare disease space, which is often characterized by high-value assets and specialized market access requirements.
• Alkermes' commitment to advancing its orexin 2 receptor agonists (ALKS 4510, ALKS 7290) and LUMRYZ's label expansion into idiopathic hypersomnia aligns with industry efforts to develop novel mechanisms of action and expand indications for sleep disorders, moving beyond traditional stimulants and sedatives.

Management Changes

Corporate Governance

Legal Proceedings

• The CVR payment is contingent upon the dismissal of specific patent infringement claims (Claims) with prejudice by the United States District Court for the District of Delaware, pursuant to a Settlement and License Agreement dated October 21, 2025, between Avadel and Jazz Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders of Avadel: Will receive $18.50 cash per share and a CVR for a potential additional $1.50 per share, representing a significant premium. The CVR introduces contingent upside but also risk.
• Employees of Avadel: Alkermes recognizes their value and will safeguard existing employment rights. However, some operational and administrative reorganization is anticipated, potentially affecting central corporate and support functions.
• Customers (patients) of LUMRYZ: The acquisition is expected to enhance the product's reach and support further development, potentially benefiting more patients.
• Alkermes Shareholders: The transaction is expected to be immediately accretive and enhance revenue growth and profitability, positioning Alkermes as a key player in sleep medicine.
• Creditors: Alkermes will incur new debt ($1.2 billion) to finance the acquisition, which will impact its debt profile.

Next Steps

• Avadel to prepare and file a proxy statement (including the Scheme Document) with the SEC and the Irish Takeover Panel by November 12, 2025.
• Avadel to hold a Scheme Meeting and an Extraordinary General Meeting (EGM) for shareholder approval of the acquisition.
• Alkermes and Avadel to obtain required antitrust clearances in the United States.
• Alkermes to secure new debt financing of $1.2 billion to supplement cash on hand for the acquisition.
• Alkermes to advance alixorexton into a Phase 3 program in narcolepsy.
• Alkermes to support the advancement of clinical studies for potential label expansion opportunities for LUMRYZ (Phase 3 for idiopathic hypersomnia).
• Alkermes to support the potential advancement of valiloxybate.
• Alkermes to engage with Avadel's senior management in integration planning, including a review of Avadel's business for operational and administrative reorganization and cost efficiencies.
• Non-executive directors of Avadel intend to resign upon completion of the acquisition.
• Delisting of Avadel shares from Nasdaq and deregistration under the Exchange Act as promptly as practicable after the Effective Time.

Key Dates

Recommendation

The acquisition offers a substantial premium of 38% to Avadel's recent trading prices, providing immediate and significant value to shareholders. The additional contingent value right (CVR) offers further upside potential, albeit with inherent risks tied to milestone achievement. For Alkermes, the acquisition is strategically sound, immediately accretive, and significantly expands its presence in a high-growth therapeutic area with a differentiated commercial product (LUMRYZ) and a pipeline of complementary assets. The financing is committed, and board approvals are in place, indicating a high likelihood of completion. This combination of immediate shareholder value for Avadel and strong strategic rationale for Alkermes makes it a compelling opportunity.

Keywords

Acquisition, Biopharmaceutical, Sleep Medicine, Narcolepsy, Idiopathic Hypersomnia, LUMRYZ, Contingent Value Right, FDA Approval, Merger, Pharmaceuticals